中國有贊(08083.HK)私有化告吹
中國有贊(08083.HK)公布,公司建議不再繼續進行私有化和實物分派有贊科技股份。有贊科技不會進一步進行就有贊科技上市作出的、並於8月重新提交的有贊科技上市申請。
公司表示,考慮到有贊科技上市申請現階段進度以及聯交所上市委員會仍未就有贊科技上市申請進行聆訊,要約人與中國有贊將無法在本年底或之前寄發包含有贊科技上市相關信息的計劃文件等,有贊科技招股書定稿及召開法院會議不再可能均於計劃最後完成日期或之前達成或獲豁免。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.